Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation

Serena Merante, Ester Orlandi, Paolo Bernasconi, Silvia Calatroni, Marina Boni, Mario Lazzarino

Research output: Contribution to journalArticlepeer-review

Abstract

Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.

Original languageEnglish
Pages (from-to)979-981
Number of pages3
JournalHaematologica
Volume90
Issue number7
Publication statusPublished - Jul 2005

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Therapy discontinuation

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation'. Together they form a unique fingerprint.

Cite this